These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 11051402)

  • 1. Idiopathic pancreatitis associated with ulcerative colitis.
    Sáez J; Martínez J; García C; Griñó P; Pérez-Mateo M
    Am J Gastroenterol; 2000 Oct; 95(10):3004-5. PubMed ID: 11051402
    [No Abstract]   [Full Text] [Related]  

  • 2. [Peripheral eosinophilia in ulcerative colitis: apropos of a case].
    Galofre N; Fuste L; Oriol A; Grau J
    Gastroenterol Hepatol; 1997 Mar; 20(3):163. PubMed ID: 9162539
    [No Abstract]   [Full Text] [Related]  

  • 3. [Idiopathic chronic pancreatitis (with diffuse stenosis of Wirsung's duct) in ulcerative colitis].
    Peña E; Moreira VF; García S; Urman J; del Pozo D; Miquel J
    Gastroenterol Hepatol; 2000 Oct; 23(8):389-91. PubMed ID: 11227653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salmonellosis and ulcerative colitis. A causal relationship or just a coincidence.
    Karaoglu AO; Yukselen V; Ertem GT; Erkus M
    Saudi Med J; 2004 Oct; 25(10):1486-8. PubMed ID: 15494829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Acute pancreatitis--induced by 5-aminosalicylic acid or an extraintestinal manifestation of ulcerative colitis?].
    Petersen HH; Skovbjerg H
    Ugeskr Laeger; 1995 Sep; 157(39):5400-1. PubMed ID: 7483055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Chronic pancreatitis: an extraintestinal manifestation of hemorrhagic rectocolitis?].
    Lederman E; Boruchowicz A; Colombel JF
    Gastroenterol Clin Biol; 1997; 21(1):71-3. PubMed ID: 9091393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial.
    Hanauer SB; Sandborn WJ; Kornbluth A; Katz S; Safdi M; Woogen S; Regalli G; Yeh C; Smith-Hall N; Ajayi F
    Am J Gastroenterol; 2005 Nov; 100(11):2478-85. PubMed ID: 16279903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Activity indices--objective criteria of the estimation of severity level of ulcerous colitis].
    Bakulin IG; Stanke DA; Belousova EA; Golovenko OV; Mikhailova TL
    Eksp Klin Gastroenterol; 2008; (6):14-6. PubMed ID: 19334421
    [No Abstract]   [Full Text] [Related]  

  • 9. Ulcerative colitis associated with leukocytoclastic vasculitis of the skin.
    Tripodi Cutrì F; Salerno R; Lo Schiavo A; Gravina AG; Romano M; Ruocco E
    Dig Liver Dis; 2009 Jul; 41(7):e42-4. PubMed ID: 18799375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis.
    Dignass AU; Bokemeyer B; Adamek H; Mross M; Vinter-Jensen L; Börner N; Silvennoinen J; Tan G; Pool MO; Stijnen T; Dietel P; Klugmann T; Vermeire S; Bhatt A; Veerman H
    Clin Gastroenterol Hepatol; 2009 Jul; 7(7):762-9. PubMed ID: 19375519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Duration of remission and long-term prognosis according to the extent of disease in patients with ulcerative colitis on continuous mesalamine treatment.
    Bresci G; Parisi G; Capria A
    Colorectal Dis; 2008 Oct; 10(8):814-7. PubMed ID: 18834420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Megacolon as a presenting finding of acute pancreatitis associated with chronic ulcerative colitis: unusual presentation of an unusual association.
    Bauer W; Tepper R; Katz S
    Am J Gastroenterol; 1995 Jun; 90(6):1013-5. PubMed ID: 7771399
    [No Abstract]   [Full Text] [Related]  

  • 13. Acute pancreatitis as a possible consequence of metronidazole during a relapse of ulcerative colitis.
    Tsesmeli NE; Giannoulis KE; Savopoulos CG; Vretou EE; Ekonomou IA; Giannoulis EK
    Eur J Gastroenterol Hepatol; 2007 Sep; 19(9):805-6. PubMed ID: 17700268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis.
    Lichtenstein GR; Kamm MA; Boddu P; Gubergrits N; Lyne A; Butler T; Lees K; Joseph RE; Sandborn WJ
    Clin Gastroenterol Hepatol; 2007 Jan; 5(1):95-102. PubMed ID: 17234558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Ulcerative colitis. When is standard therapy enough?].
    Stange EF
    MMW Fortschr Med; 2000 Oct; 142(41):39-40. PubMed ID: 11085075
    [No Abstract]   [Full Text] [Related]  

  • 16. [Patients prefer foam].
    MMW Fortschr Med; 2007 May; 149(21):48. PubMed ID: 17668735
    [No Abstract]   [Full Text] [Related]  

  • 17. The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine.
    Kruis W; Bar-Meir S; Feher J; Mickisch O; Mlitz H; Faszczyk M; Chowers Y; Lengyele G; Kovacs A; Lakatos L; Stolte M; Vieth M; Greinwald R
    Clin Gastroenterol Hepatol; 2003 Jan; 1(1):36-43. PubMed ID: 15017515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Balsalazide plus high-potency probiotic preparation (VSL[sharp]3) in the treatment of acute mild-to-moderate ulcerative colitis and uncomplicated diverticulitis of the colon.
    Tursi A
    J Clin Gastroenterol; 2008 Sep; 42 Suppl 3 Pt 1():S119-22. PubMed ID: 18806701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial.
    Hanai H; Iida T; Takeuchi K; Watanabe F; Maruyama Y; Andoh A; Tsujikawa T; Fujiyama Y; Mitsuyama K; Sata M; Yamada M; Iwaoka Y; Kanke K; Hiraishi H; Hirayama K; Arai H; Yoshii S; Uchijima M; Nagata T; Koide Y
    Clin Gastroenterol Hepatol; 2006 Dec; 4(12):1502-6. PubMed ID: 17101300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MMX mesalamine.
    Baker DE
    Rev Gastroenterol Disord; 2006; 6(3):146-52. PubMed ID: 16957657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.